

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	2
INTENDED AUDIENCE.....	2
SCOPE OF REPORT.....	3
METHODOLOGY.....	3
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER.....	4
CHAPTER TWO: SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL MARKET REVENUE FORECAST FOR STEM CELL THERAPEUTIC REGIMENS IN ONCOLOGY, THROUGH 2015 (\$ MILLIONS)</i> .....	5
<i>SUMMARY FIGURE GLOBAL MARKET REVENUE FORECAST FOR STEM CELL THERAPEUTIC REGIMENS IN ONCOLOGY, 2008-2015 (\$ MILLIONS)</i> .....	6
CHAPTER THREE: OVERVIEW.....	7
HISTORY AND CURRENT STATE OF ONCOLOGY, AND CORE CONCEPTS OF STEM CELL BASED THERAPEUTICS AND REGENERATIVE MEDICINE.....	7
HISTORY OF ONCOLOGY.....	7
HISTORY OF STEM CELLS IN ONCOLOGY.....	8
A BRIEFING ON THE HISTORY OF STEM CELLS AS THERAPEUTICS, AND A FEW KEY ISSUES TO KEEP IN MIND.....	9
OTHER RELEVANT HISTORY.....	10
TYPES OF CANCER.....	11
<i>TABLE 1 TYPES OF CANCER INCLUDED IN THIS REPORT</i> .....	12
<i>TABLE 2 COMMON TYPES OF LYMPHOMA</i> .....	13
DEFINITION OF THE INDUSTRY.....	14
IMPORTANCE OF THE INDUSTRY.....	14
PRODUCT LIFE CYCLES.....	15
<i>TABLE 3 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG</i> .....	16
DEVELOPMENT OF STEM CELLS IN ONCOLOGY.....	16
<i>TABLE 4 HISTORICAL PIPELINE OF FDA APPROVED THERAPEUTICS RELATING TO STEM AND PROGENITOR CELLS</i> .....	17
HUMAN CLINICAL DEVELOPMENT.....	17
NEW DRUG ACTIVITY.....	18
FUTURE DEVELOPMENTS.....	18

SIGNIFICANT “NEW” CLINICAL DEVELOPMENTS 2008 TO PRESENT.....	18
Significant “New” Clinical ... (Continued).....	19
<i>TABLE 5 KEY PHASE III AND IV STEM CELL CLINICAL TRIALS WITH ESTIMATED COMPLETION DATES BETWEEN 2008 AND 2019.....</i>	<i>20</i>
WITH AN EYE TOWARD THE FUTURE.....	21
WITH AN EYE TOWARD THE FUTURE (CONTINUED) .....	22
CHAPTER FOUR: TYPES OF APPLICATIONS: AUTOLOGOUS, ALLOGENEIC, HEALTHY STEM CELL PROMOTER, TUMOR STEM CELL INHIBITOR .....	23
TYPES OF APPLICATIONS: AUTOLOGOUS.....	23
TYPES OF APPLICATIONS: AUTOLOGOUS... (CONTINUED).....	24
HUMAN CANCERS.....	25
<i>TABLE 6 REVENUES OF STEM CELL ONCOLOGY REGIMENS BROKEN DOWN BY CANCER INDICATION, THROUGH 2015 (\$ MILLIONS).....</i>	<i>26</i>
<i>FIGURE 1 REVENUES OF STEM CELL ONCOLOGY REGIMENS BROKEN DOWN BY CANCER INDICATION, 2008-2015 (\$ MILLIONS).....</i>	<i>27</i>
RISK FACTORS FOR DEVELOPING CANCERS .....	27
<i>TABLE 7 RISK FACTORS ASSOCIATED WITH HUMAN CANCERS.....</i>	<i>28</i>
<i>TABLE 7 (CONTINUED).....</i>	<i>29</i>
<i>TABLE 8 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN MEN.....</i>	<i>30</i>
<i>TABLE 9 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN WOMEN .....</i>	<i>30</i>
<i>TABLE 10 HUMAN CANCER SURVIVAL STATISTICS BY ETHNIC BACKGROUND (%).....</i>	<i>31</i>
<i>TABLE 11 ESTIMATED HUMAN CANCER TRENDS, 2008-2015.....</i>	<i>31</i>
BREAST.....	32
<i>TABLE 12 BREAST CANCER: SIGNS AND SYMPTOMS.....</i>	<i>32</i>
<i>TABLE 13 BREAST CANCER: RISK FACTORS.....</i>	<i>33</i>
<i>TABLE 14 KEY GENETIC FACTORS ASSOCIATED WITH BREAST CANCER.....</i>	<i>33</i>
<i>TABLE 14 (CONTINUED).....</i>	<i>34</i>
<i>TABLE 15 CLINICAL TRIALS THAT INCLUDE STEM CELL–BASED THERAPEUTICS FOR BREAST CANCER.....</i>	<i>35</i>
RECTUM AND COLON.....	35
<i>TABLE 16 COLON AND RECTUM CANCERS: SIGNS AND SYMPTOMS.....</i>	<i>36</i>
<i>TABLE 17 COLON AND RECTUM CANCERS: RISK FACTORS .....</i>	<i>36</i>
<i>TABLE 18 KEY GENETIC FACTORS ASSOCIATED WITH CANCERS OF THE COLON AND RECTUM .....</i>	<i>37</i>

<i>TABLE 19 CLINICAL TRIALS THAT INCLUDE STEM CELL–BASED THERAPEUTICS FOR COLON OR RECTAL CANCERS.....</i>	<i>38</i>
<i>TABLE 20 REVENUES FOR STEM CELL BASED REGIMENS FOR COLORECTAL CANCER BY GEOGRAPHICAL REGION, THROUGH 2015 .....</i>	<i>39</i>
<i>LYMPHOMA .....</i>	<i>39</i>
<i>TABLE 21 LYMPHOMAS: SIGNS AND SYMPTOMS .....</i>	<i>39</i>
<i>TABLE 22 LYMPHOMAS: RISK FACTORS.....</i>	<i>39</i>
<i>TABLE 23 KEY GENETIC FACTORS ASSOCIATED WITH LYMPHOMAS.....</i>	<i>40</i>
<i>TABLE 24 REVENUES FOR STEM CELL BASED REGIMENS FOR LYMPHOMAS BY GEOGRAPHICAL REGION, THROUGH 2015 (\$ MILLIONS).....</i>	<i>41</i>
<i>TABLE 25 CLINICAL TRIALS THAT INCLUDE STEM CELL–BASED THERAPEUTICS FOR LYMPHOMA.....</i>	<i>41</i>
<i>TABLE 25 (CONTINUED).....</i>	<i>42</i>
<i>TABLE 25 (CONTINUED).....</i>	<i>43</i>
<i>LUNG.....</i>	<i>43</i>
<i>TABLE 26 LUNG CANCERS: SIGNS AND SYMPTOMS.....</i>	<i>43</i>
<i>TABLE 27 LUNG CANCERS: RISK FACTORS .....</i>	<i>44</i>
Non–small Cell Lung Cancer .....	44
Small Cell Lung Cancer .....	44
<i>TABLE 28 KEY GENETIC FACTORS ASSOCIATED WITH LUNG CANCERS .....</i>	<i>45</i>
<i>TABLE 29 CLINICAL TRIALS THAT INCLUDE STEM CELL–BASED THERAPEUTICS FOR LUNG CANCERS.....</i>	<i>45</i>
<i>TABLE 30 REVENUES FOR STEM CELL BASED REGIMENS FOR LUNG CANCER BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>46</i>
<i>LEUKEMIA .....</i>	<i>46</i>
<i>TABLE 31 LEUKEMIA: SIGNS AND SYMPTOMS .....</i>	<i>46</i>
<i>TABLE 32 LEUKEMIA: RISK FACTORS.....</i>	<i>47</i>
<i>TABLE 33 KEY GENETIC FACTORS ASSOCIATED WITH LEUKEMIAS.....</i>	<i>47</i>
<i>TABLE 34 CLINICAL TRIALS THAT INCLUDE STEM CELL–BASED THERAPEUTICS FOR LEUKEMIAS.....</i>	<i>48</i>
<i>TABLE 35 REVENUES FOR STEM CELL BASED REGIMENS FOR LEUKEMIA BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>49</i>
<i>PROSTATE CANCER.....</i>	<i>49</i>
<i>TABLE 36 PROSTATE CANCER: SIGNS AND SYMPTOMS.....</i>	<i>49</i>
<i>TABLE 37 PROSTATE CANCER: RISK FACTORS.....</i>	<i>50</i>
<i>TABLE 38 KEY GENETIC FACTORS IN PROSTATE CANCERS.....</i>	<i>50</i>
<i>TABLE 39 CLINICAL TRIALS THAT INCLUDE STEM CELL–BASED THERAPEUTICS FOR PROSTATE CANCERS .....</i>	<i>51</i>

SPONSORS: M.D. ANDERSON CANCER CENTER; CELGENE CORPORATION .....	51
MULTIPLE MYELOMA .....	51
TABLE 40 REVENUES FOR STEM CELL BASED REGIMENS FOR MULTIPLE MYELOMA BY GEOGRAPHICAL REGION, THROUGH 2015 (\$ MILLIONS).....	52
TABLE 41 CLINICAL TRIALS THAT INCLUDE A STEM CELL–BASED THERAPEUTICS FOR MULTIPLE MYELOMA .....	52
TABLE 41 (CONTINUED).....	53
TABLE 41 (CONTINUED).....	54
TABLE 41 (CONTINUED).....	55
TABLE 41 (CONTINUED).....	56
GASTRIC .....	57
TABLE 42 KEY GENETIC FACTORS IN GASTRIC CANCERS .....	57
TABLE 43 CLINICAL TRIALS THAT INCLUDE STEM CELL BASED THERAPEUTICS FOR GASTRIC CANCERS.....	58
SKIN CANCER .....	58
TABLE 44 SKIN CANCER: SIGNS AND SYMPTOMS.....	59
TABLE 45 SKIN CANCER: RISK FACTORS .....	59
TABLE 46 KEY GENETIC FACTORS IN SKIN CANCERS.....	60
TABLE 47 REVENUES FOR STEM CELL–BASED REGIMENS FOR SKIN CANCERS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS) .....	60
TABLE 48 CLINICAL TRIALS THAT INCLUDE STEM CELL BASED THERAPEUTICS FOR SKIN CANCERS .....	61
CHAPTER FIVE: STEM CELL–BASED THERAPIES IN HUMAN ONCOLOGY SETTINGS .....	62
STEM CELL–BASED THERAPIES.....	62
TABLE 49 ONCOLYTIC STEM CELL REVENUES BY DEVELOPMENT/APPROVAL STATUS: ALL PRODUCT TYPES, THROUGH 2015 (\$ MILLIONS).....	63
THERAPEUTIC OR ADJUVANT REVENUES AND PRODUCTS .....	63
TABLE 50 ONCOLOGY STEM CELL BASED THERAPEUTICS REVENUES BY THERAPY TYPE, THROUGH 2015 (\$ MILLIONS).....	63
FIGURE 2 ONCOLOGY STEM CELL BASED THERAPEUTICS REVENUES BY THERAPY TYPE, THROUGH 2015 (\$ MILLIONS).....	64
ALLOGENEIC THERAPEUTICS .....	64
TABLE 51 REVENUES AND FORECAST OF ALLOGENEIC THERAPEUTICS BROKEN DOWN BY GEOGRAPHICAL REGION, THROUGH 2015 (\$ MILLIONS).....	64
Revlimid .....	65
StemEx.....	65
AUTOLOGOUS THERAPEUTICS.....	65

<i>TABLE 52 REVENUES AND FORECAST OF AUTOLOGOUS THERAPEUTICS BROKEN DOWN BY GEOGRAPHICAL REGION, THROUGH 2015 (\$ MILLIONS)</i> .....	65
StemEx.....	66
Mozobil.....	66
Genzyme’s – Mozobil.....	66
TUMOR INHIBITOR THERAPEUTICS .....	66
<i>TABLE 53 REVENUES AND FORECAST OF TUMOR INHIBITOR THERAPEUTICS BROKEN DOWN BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i> .....	66
IPI-926.....	67
VGX-3100 .....	67
XL139 .....	67
GDC-0449.....	67
CELL MOBILIZER THERAPEUTICS.....	68
<i>TABLE 54 REVENUES AND FORECAST OF HEALTHY CELL MOBILIZER THERAPEUTICS BROKEN DOWN BY GEOGRAPHICAL REGION, THROUGH 2015 (\$ MILLIONS)</i> .....	68
Wyeth (now Pfizer) Neumega.....	68
THERAPEUTIC OR ADJUVANT BY CANCER INDICATION.....	68
<i>TABLE 55 ONCOLOGY STEM CELL BASED THERAPEUTIC UTILIZED BY STAGE OF CANCER BROKEN DOWN BY CANCER INDICATION</i> .....	68
<i>TABLE 55 (CONTINUED)</i> .....	69
ALLOGENEIC THERAPEUTIC .....	69
<i>TABLE 56 REVENUES AND FORECAST OF ALLOGENEIC STEM CELL TRANSPLANT ANTICANCER THERAPEUTICS BY INDICATION THROUGH 2015 (\$ MILLIONS)</i> .....	69
<i>TABLE 57 REVENUES AND FORECAST OF ALLOGENEIC STEM CELL TRANSPLANT ANTICANCER THERAPEUTICS BY INDICATION, FDA APPROVED, 2008 THROUGH 2015 (\$ MILLIONS)</i> .....	70
<i>TABLE 58 REVENUES AND FORECAST OF ALLOGENEIC STEM CELL TRANSPLANT ANTICANCER THERAPEUTICS BY INDICATION, PHASE III APPROVED, 2008 THROUGH 2015 (\$ MILLIONS)</i> .....	70
AUTOLOGOUS THERAPEUTICS.....	70
<i>TABLE 59 REVENUES AND FORECAST OF AUTOLOGOUS STEM CELL TRANSPLANT ANTICANCER THERAPEUTICS BY INDICATION THROUGH 2015 (\$ MILLIONS)</i> .....	71
<i>TABLE 60 REVENUES AND FORECAST OF AUTOLOGOUS STEM CELL TRANSPLANT ANTICANCER THERAPEUTICS BY INDICATION, FDA APPROVED, THROUGH 2015 (\$ MILLIONS)</i> .....	71

TABLE 61 REVENUES AND FORECAST OF AUTOLOGOUS STEM CELL TRANSPLANT ANTICANCER THERAPEUTICS BY INDICATION, PHASE III, THROUGH 2015 (\$ MILLIONS).....	71
TUMOR INHIBITORS.....	72
TABLE 62 REVENUE AND FORECAST OF STEM CELL BASED TUMOR INHIBITORS BY INDICATION, THROUGH 2015 (\$ MILLIONS).....	72
TABLE 63 REVENUE AND FORECAST OF STEM CELL BASED TUMOR INHIBITORS BY INDICATION PHASE III, THROUGH 2015 (\$ MILLIONS).....	72
TABLE 64 REVENUE AND FORECAST OF STEM CELL BASED TUMOR INHIBITORS BY INDICATION RESEARCH, THROUGH 2015 (\$ MILLIONS).....	73
HEALTHY STEM CELL MOBILIZER/STIMULATORS .....	73
TABLE 65 REVENUE AND FORECAST OF STEM CELL BASED HEALTHY CELL MOBILIZERS BY INDICATION, THROUGH 2015 (\$ MILLIONS).....	73
TABLE 66 REVENUE AND FORECAST OF STEM CELL BASED HEALTHY CELL MOBILIZERS BY INDICATION, FDA APPROVED, THROUGH 2015 (\$ MILLIONS).....	74
TABLE 67 REVENUE AND FORECAST OF STEM CELL BASED HEALTHY CELL MOBILIZERS BY INDICATION, RESEARCH PHASE, THROUGH 2015 (\$ MILLIONS).....	74
CHAPTER SIX: TRADITIONAL MEDICINES.....	75
A BRIEF HISTORY OF NATURAL MEDICINES .....	75
MORE CURRENT FDA APPROVALS OF NATURAL MEDICINES.....	76
NATURAL PRODUCTS IN CLINICAL TRIALS .....	77
TABLE 68 CLINICAL TRIALS OF STEM CELL RELATED THERAPETUICS THAT HAVE A NATURALLY DERIVED ANTITUMOR ADJUVANT.....	77
TABLE 68 (CONTINUED).....	78
CHAPTER SEVEN: GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS .....	79
GOVERNMENT AGENCIES .....	79
GOVERNMENT AGENCIES (CONTINUED).....	80
GOVERNMENT AGENCIES (CONTINUED).....	81
FOOD AND DRUG ADMINISTRATION .....	82
BIOLOGICS.....	82
ONCOLOGY ADJUVANTS .....	83
STATE LEVEL RESEARCH .....	84
TABLE 69 STATES IN THE U.S. THAT PERMIT STEM CELL RESEARCH.....	84

<i>TABLE 70 STATES IN THE U.S. THAT PROHIBIT STEM CELL RESEARCH</i> .....	85
CALIFORNIA .....	85
TEXAS .....	86
INTERNATIONAL STEM CELL RESEARCH .....	87
<i>TABLE 71 COUNTRIES PRODUCING STEM CELL RESEARCH</i> .....	87
PROFESSIONAL ASSOCIATIONS.....	87
AMERICAN ASSOCIATION FOR CANCER RESEARCH.....	87
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO).....	88
 CHAPTER EIGHT: MAJOR ONCOLYTIC STEM CELL	
MANUFACTURERS .....	89
STEM CELL MANUFACTURERS .....	89
<i>TABLE 72 MAJOR STEM CELL ONCOLOGY HUMAN</i>	
<i>PHARMACEUTICAL MANUFACTURERS</i> .....	90
<i>FIGURE 3 PERCENTAGE OF ONCOLOGY STEM CELL</i>	
<i>THERAPUTICS PHARMACEUTICAL MANUFACTURERS BY</i>	
<i>COUNTRY (%)</i> .....	91
MAJOR PHARMACEUTICAL MANUFACTURER PROFILES .....	91
CELGENE .....	92
COMBINATRIX CORPORATION.....	92
CURIS, INC. ....	92
EXELIXIS, INC .....	93
F. HOFFMANN–LA ROCHE LTD .....	94
GERON CORPORATION .....	94
GENZYME.....	94
INOVIO BIOMEDICAL CORPORATION .....	95
MERCK.....	96
MICROMET, INC.....	96
PFIZER, INC. ....	97
TEVA PHARMACEUTICAL INDUSTRIES LTD.....	97
 CHAPTER NINE: ONCOLYTIC STEM CELL THERAPUTICS INDUSTRY.....	98
ONCOLOGIC STEM CELL MARKET TRENDS: HUMAN	
HEALTHCARE.....	98
ACCELERATING STEM CELL THERAPIES IN ONCOLOGY.....	98
LEUKEMIA.....	99
LYMPHOMA .....	99
MULTIPLE MYELOMA .....	99
<i>TABLE 73 NEW PRESCRIPTION ONCOLOGY STEM CELL</i>	
<i>THERAPETUICS, 2008</i> .....	100
<i>TABLE 74 ONCOLOGY STEM CELL THERAPEUTIC REGIMIENS IN</i>	
<i>THE CLINICAL TRIAL PIPELINE, 2009</i> .....	101
NEED TO INCREASE USE AND ACCEPTANCE OF NEWER DRUGS....	101

CHAPTER TEN: PATENT ANALYSIS .....	102
PURPOSE OF A PATENT ANALYSIS.....	102
DUE CARE IN REVIEWING THE PATENT ANALYSIS.....	102
NEW ONCOLOGY STEM CELL THERAPEUTIC PATENTS ISSUED .....	103
<i>TABLE 75 ONCOLOGY STEM CELL THERAPEUTIC PATENT</i>	
<i>TRENDS, 1990-2009.....</i>	103
<i>FIGURE 4 ONCOLOGY STEM CELL THERAPEUTICS PATENT</i>	
<i>TRENDS 1990-2009.....</i>	104
<i>TABLE 76 PATENTS BY ONCOLOGY STEM CELL – THERAPY TYPE</i>	
2007-2009 .....	105
<i>TABLE 77 NEW ANTI-TUMOR THERAPIES RELATING TO STEM</i>	
<i>CELLS PATENTS ISSUED, 2007-2009.....</i>	106
<i>TABLE 77 (CONTINUED).....</i>	107
<i>TABLE 77 (CONTINUED).....</i>	108
<i>TABLE 78 ASSIGNEES OF TWO OR MORE PATENTS FOR</i>	
<i>ONCOLOGY STEM CELL THERAPEUTICS, 2007–2009.....</i>	109
<i>TABLE 79 NEW STEM CELL THERAPAUTIC ONCOLOGY PATENT</i>	
<i>APPROVALS BY COUNTRY, 2007-2009 (NO./%).....</i>	109
<i>FIGURE 5 NEW STEM CELL THERAPAUTIC ONCOLOGY PATENT</i>	
<i>APPROVALS BY COUNTRY, 2007-2009 (%).....</i>	110
TRENDS IN PATENT APPLICATIONS .....	110
<i>TABLE 80 NEW STEM CELL THERAPAUTIC ONCOLOGY PATENT</i>	
<i>APPLICATIONS BY YEAR, 2001 THROUGH 2009 (NO./%) .....</i>	111
<i>FIGURE 6 NEW STEM CELL THERAPAUTIC ONCOLOGY PATENT</i>	
<i>APPLICATIONS, BY YEAR, 2001-2009 (%).....</i>	112
<i>TABLE 81 PATENT APPLICATIONS BY ONCOLOGY NEW STEM</i>	
<i>CELL THERAPAUTIC THERAPY TYPE, 2007-2009 (NO./%).....</i>	112
<i>FIGURE 7 PERCENTAGE OF PATENT APPLICATIONS BY</i>	
<i>ONCOLOGY NEW STEM CELL THERAPAUTIC MARKET</i>	
<i>SEGMENT, 2007-2009 (%).....</i>	113
<i>TABLE 82 NEW PATENT APPLICATIONS, 2007-2009.....</i>	113
<i>TABLE 82 (CONTINUED).....</i>	114
<i>TABLE 82 (CONTINUED).....</i>	115
<i>TABLE 82 (CONTINUED).....</i>	116
<i>TABLE 82 (CONTINUED).....</i>	117
<i>TABLE 82 (CONTINUED).....</i>	118
<i>TABLE 83 RECENT TRENDS IN PATENT APPLICATIONS FOR</i>	
<i>ONCOLOGY STEM CELL THERAPEUTICS BY MARKET</i>	
<i>SEGMENT, 2007-2009 (NO./%).....</i>	119
<i>TABLE 84 ONCOLOGY STEM CELL THERAPEUTICS PATENT</i>	
<i>APPLICATIONS BY COUNTRY, 2007-2009 (NO./%) .....</i>	119
<i>FIGURE 8 ONCOLOGY STEM CELL THERAPEUTICS PATENT</i>	
<i>APPLICATIONS BY COUNTRY, 2007-2009 (%).....</i>	120
PATENT EXPIRATIONS .....	120



<i>TABLE 85 PATENT EXPIRATIONS</i> .....	121
CHAPTER ELEVEN: APPENDIX.....	122
<i>TABLE 86 COMPANIES</i> .....	122